BRIEF—I-Mab reportedly set to go public in USA

China-based drug developer I-Mab Biopharma has  reportedly filed for an initial public offering (IPO) in the USA, which could raise up to $200 million.

Based on a private funding round which is currently underway, led by WuXi Biologics among others, the business would be valued at around $800 million, with up to $40 million likely to be raised in the financing.

The company is focused on developing treatments for cancer and autoimmune diseases.